Global Viral Vector and Vaccine Market – Industry Trends and Forecast to 2030

Global Viral Vector and Vaccine Market, By Type (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others), Workflow Upstream Processing, Downstream Processing, Application (Antisense and RNAi, Gene Therapy, Cell Therapy, Vaccinology), Disease (Cancer, Genetic Disorders, Infectious Diseases, Others), End Use (Pharmaceutical and Biopharmaceutical Companies, Research Institutes) – Industry Trends and Forecast to 2030.

Viral Vector and Vaccine Market Analysis and Size

The introduction of novel therapies based on vectors, such as gene therapy and cell therapy, has sparked great interest in the medical community in recent decades. Therapies involving genetic modification, such as the introduction of therapeutic DNA/gene into a patient's body or cell, have demonstrated great promise in the treatment of cancer, Alzheimer's disease, Parkinson's disease, and rheumatoid arthritis, among other disorders.

Data Bridge Market Research analyses that the viral vector and vaccine market which is USD 513.43 million in 2022, is expected to reach USD 2016.62 million by 2030, at a CAGR of 18.65% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Viral Vector and Vaccine Market Scope and Segmentation

Market Definition

A vector is a type of gene delivery device used to introduce a transgene into a cell where it can be replicated and/or expressed. The vector is a DNA molecule that contains a transgene insert as well as a longer sequence that acts as the vector's pillar. The vector's basic functions in conveying genetic information to another cell are the isolation, multiplication, or expression of the insert in the target cell.

Viral Vector and Vaccine Market Dynamics

Drivers

• Rising prevalence of cancer and genetic disorders

Lung cancer is the leading cause of cancer death, according to the World Health Organization, followed by breast cancer and colorectal cancer. One of the primary drivers of the global viral vector and vaccine market is the increasing prevalence of cancer, genetic illnesses, and infectious diseases, which is increasing demand for vector-based gene treatments, cell therapies, and vaccines.

• Rapid uptake of viral and plasmid vectors for the development of innovative therapies

Novel medicines are being developed at a rapid pace using viral and non-viral vectors. These vectors can deliver a gene to a specific cell or tissue in vivo. Adeno-associated virus, lentivirus, and retrovirus are examples of viral vectors used in clinical and preclinical trials to evaluate gene and cell therapy products and vaccines.

Opportunities

• Rising prevalence of diseases

The increasing prevalence of diseases such as heart disease, cancer, HIV, and haemophilia has necessitated the development of viral vector-based therapeutics, with technological advancements in viral vector manufacturing driving market growth. In addition, the increasing use of viral vectors in the biopharmaceutical industry, as well as the need for more cost-effective treatments, are driving market demand. However, the underdeveloped medical industry in some areas, as well as increased government activities in the healthcare R&D sector, will provide profitable opportunities in the coming years.

Restraints/Challenges

• High cost

The lack of skilled professionals and high cost are factors restraining market growth. The main disadvantages of viral vector vaccines are that they have a more complex manufacturing process, they risk genomic integration, host-induced neutralising antibodies to the carrier virus can develop, and/or it may not be possible to use the same technology for repeated vaccinations.
This viral vector and vaccine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the viral vector and vaccine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Viral Vector and Vaccine Market

Due to the devastating COVID-19 pandemic, vaccine development against SARS-CoV-2 has been intense, encompassing all conceivable options for providing the global community with safe and effective vaccine candidates in the shortest timeframe possible. Viral vectors, particularly adenovirus-based vectors, have been crucial. Vaccines based on viral vectors such as vaccinia, measles, rhabdoviruses, influenza viruses, and lentiviruses have also been developed. Self-amplifying RNA viral vectors delivered by lipid nanoparticles were used to create COVID-19 vaccines. Several adenovirus-based vaccine candidates elicited strong immune responses in inoculated animals, and mice and primates were shielded from challenges. Furthermore, adenovirus-based vaccination candidates have gone through phase I, II, and III clinical trials. The simian adenovirus-based ChAdOx1 vector expressing the SARS-CoV-2 S spike protein was recently approved for use in clinical trials in the UK.

Recent Development

• In 2019, The US Food and Drug Administration approved Zolgensma (onasemnogene abeparvovec-xioi), an adeno-associated virus vector-based gene therapy for the treatment of pinal muscular atrophy (SMA) in infants under the age of two.

Global Viral Vector and Vaccine Market Scope

The viral vector and vaccine market is segmented on the basis of type, workflow, application, disease and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Adenovirus
• Fowlpox Virus
• Attenuated Yellow Fever
• Vaccinia Virus Vectors
• Others

Workflow

• Upstream Processing
• Downstream Processing

Application

• Antisense and RNAi
• Gene Therapy
• Cell Therapy
• Vaccinology

 Disease

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others

End-User

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

Viral Vector and Vaccine Market Regional Analysis/Insights

The viral vector and vaccine market is analyzed and market size insights and trends are provided by country, type, workflow, application, disease and end-user as referenced above.

The countries covered in the viral vector and vaccine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America is anticipated to dominate the market share due to increasing infectious disease patients.

Asia-Pacific is expected to be fastest growing region in forecast period due to clinical transformation and industrialization of gene therapy manufacturing.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The viral vector and vaccine market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for viral vector and vaccine market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the viral vector and vaccine market. The data is available for historic period 2011-2021.

Competitive Landscape and Viral Vector and Vaccine Market Share Analysis

The viral vector and vaccine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to viral vector and vaccine market.

Some of the major players operating in the viral vector and vaccine market are:

• Novasep (France)
• MerckKGaA (Germany)
• Charles River Laboratories (U.K.)
• uniQure N.V. (Netherlands)
• Waisman Biomanufacturing  (U.S.)
• Creative-Biogene (U.S.)
• Aldevron (U.S.)
• Addgene (U.S.)
• Oxford Biomedica (U.K.)
• Thermo Fisher Scientific Inc (U.S.)
• Fujifilm Corporation (Japan)
• Spark Therapeutics Inc. (U.S.)
• ABL Inc. (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• Brammer Bio (U.S.)
• Creative Biogene
• General Electric (U.S.)
• Pfizer Inc. (U.S.)